A Randomized, Open-Label, Single-Dose, Parallel-Group Study to Evaluate the Relative Bioavailability of LY03010 versus Xeplion® after Intramuscular Injection in Healthy Subjects
This is a very early stage study, called a Phase I trial. It's looking at a new medicine for schizophrenia, LY03010, and comparing it to an existing medicine called Xeplion®. The main goal is to check if these two medicines are absorbed and used by the body in a similar way when given as a single injection. This helps researchers understand if LY03010 could be a good alternative treatment. The study involves healthy people, not those with schizophrenia, to clearly see how the medicines act in a healthy system without other health conditions getting in the way. It's about ensuring the new medicine behaves as expected.
At a glance
What is this study about?
This research is a very important early step in developing new medicines. It's called a 'bioequivalence' study, which simply means we're checking if two medicines are essentially the same in how they work inside your body. Think of it like comparing two different brands of a painkiller; they both have the same active ingredient and should work in a very similar way. In this case, researchers want to see if LY03010, a new medicine, is absorbed and used by the body just like Xeplion®, an established treatment for schizophrenia.
Schizophrenia is a long-term mental health condition that can cause a range of different psychological symptoms. Medicines like Xeplion® help to manage these symptoms and improve quality of life. By comparing LY03010 to Xeplion®, the researchers are trying to find out if the new medicine could be a safe and effective treatment option in the future. This kind of study helps us understand if new versions of medicines can be just as good as the ones we already use.
Because this is a very early study, it involves healthy volunteers. This allows researchers to focus purely on how the medicines are absorbed and handled by the body, without other health conditions affecting the results. It's a crucial step before any new medicine can be tested in people who actually have the condition it's meant to treat.
Key takeaways
- This study compares a new medicine (LY03010) with an existing one (Xeplion®) for schizophrenia.
- It's an early-stage study to see if both medicines act the same way in the body.
- Healthy volunteers aged 18 and over are needed, both men and women.
- Participation involves a single injection and follow-up health checks and blood tests.
- The goal is to understand how the new medicine is absorbed and used by the body.
Who may be eligible?
To take part in this study, you need to be a healthy adult aged 18 or older. Both men and women are welcome to participate. The study is particularly looking for healthy people who don't have any major medical conditions.
Since this study is designed to see how the medicine acts in a healthy body, you wouldn't be able to join if you have schizophrenia or other significant health problems that might affect how your body responds to the medicine. The research team will do careful health checks to make sure it's safe for you to take part.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you generally in good health?
- Do you not have schizophrenia or other serious health conditions?
- Are you able to attend all required study appointments?
What does participation involve?
If you decide to take part, you would be given a single injection of either LY03010 or Xeplion®. You wouldn't know which one you're getting, and neither would the research team, to keep the results fair. After the injection, you would have regular blood tests and health checks over a period of time to see how the medicine moves through your body and how long it stays there. You might need to stay at a clinic for part of the study, and there would be several follow-up visits or phone calls. The total time you'd be involved in the study would depend on how long it takes to fully track the medicine's effects.
Potential risks and benefits
Locations (1)
- —UnverifiedPortugal
Common questions
What is bioequivalence?
Bioequivalence means that two medicines work in essentially the same way in the body, delivering the same amount of active ingredient at the same speed. It's like ensuring two different brands of the same medication are equally effective.
Why are healthy people in the study if it's for schizophrenia?
Because this is an early stage study, using healthy volunteers helps researchers understand how the medicine behaves in the body without other health conditions confusing the results. This makes sure the medicine is safe and predictable in healthy adults before it's tested in patients.
Will I know which medicine I'm given?
No, this study is 'blinded', meaning neither you nor the research team will know if you received LY03010 or Xeplion®. This helps to prevent any bias and ensures the results are as accurate as possible.
What kind of commitment is joining this study?
You'll have a single injection and then attend several follow-up appointments, which may involve blood tests and health checks, over a set period. The exact number of visits and the total duration will be clearly explained by the study team.
What if I change my mind about participating?
You are free to withdraw from the study at any time, for any reason, without needing to give an explanation. Your decision will not affect your relationship with your doctor or any future medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.